PM2.5 Exposure Linked to Asthma Rescue Medication Use
MONDAY, Dec. 10, 2018 -- For individuals with asthma, increased fine particulate matter (PM2.5) exposure is associated with increased weekly rescue inhaler use, according to a study published online Nov. 26 in the Proceedings of the National Academy of Sciences.
Austin M. Williams, from the University of Wisconsin-Madison, and colleagues used a nationwide panel dataset tracking the use of rescue medications among 2,874 individuals with asthma and their exposure to PM2.5 concentration between 2012 and 2017. The sample consisted of individuals using an asthma digital health platform, which made use of a wireless sensor to track the place and time of inhaler use and nonevent location and time indicators.
The researchers found that a 1 µg/m³ (12 percent) increase in weekly exposure to PM2.5 was correlated with a 0.82 percent increase in weekly inhaler use. They observed seasonal, regional, and income-based heterogeneity in the response. A reduction of 1 µg/m³ in particulate matter concentration nationwide would yield economic benefits of nearly $350 million annually based on response prediction and estimates from the literature on willingness to pay to avoid asthma symptoms.
"Initiatives that seek health and productivity improvements via pollution reductions are likely to generate ecological benefits simultaneously, while also pushing human capital and wealth toward levels where environmental sustainability becomes important for broader sets of reasons," the authors write.
One author disclosed financial ties to Propeller Health, which distributes the asthma management platform on which the data are based.
© 2020 HealthDay. All rights reserved.
Posted: December 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.